Welcome to the Lantheus Fourth Quarter and Full Year 2024 Conference Call. [Operator Instructions]. This call is being recorded and a replay will be available in the Investors section of the company's ...

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 ...

We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...

In the fourth quarter of 2024, the US Gross Domestic Product (GDP) expanded at an annual rate of 2.3%, slightly below market ...

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics. Lantheus ...

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics.

“With Evergreen's manufacturing and development capabilities, we become fully integrated. We are pleased to welcome Evergreen's talented team to Lantheus and are confident that their expertise in ...

BBJ's Don Seiffert has the details. Lantheus Holdings Inc. is acquiring Evergreen Theragnostics Inc., a clinical-stage radiopharmaceutical company, in a deal worth about $1B. Beauty brands ...

Last week, Lantheus announced plans to acquire clinical stage radiopharma CDMO Evergreen Theragnostics for an upfront payment of $250m, with the potential for an additional $752.5m in milestone ...

On the M&A front, Lantheus announced it is expanding its radiopharmaceutial portfolio with the acquisition of Evergreen Theragnostics, and its lead product Octevy, for around $1 billion. Also of note, ...